MGI Tech Co., Ltd., a developer of advanced life sciences technologies, and JCBio Co., Ltd., a biotechnology company in South Korea, have entered into a Memorandum of Understanding (MoU) to begin the DCS Lab Project. The collaboration sets out to advance multi-omics research while broadening the scope of novel sequencing applications, precision medicine, clinical translation, and data insights powered by artificial intelligence. By bringing together MGI’s advanced omics technologies with JCBio’s local expertise, the initiative aims to empower researchers and clinicians and reinforce South Korea’s position as a leading centre for genomics and biotechnology.
As multi-omics continues to redefine the healthcare sector, the MGI Tech and JCBio partnership represents a decisive move toward building a stronger genomic ecosystem in the country. Through access to MGI’s proprietary short-read and long-read sequencing systems, JCBio’s laboratories will be able to operate with end-to-end multi-omics capabilities. This expanded capacity allows researchers to tackle complex biological challenges with sharper precision and efficiency.
Using the DCS Lab Project, JCBio can implement innovative sequencing strategies, increase integrated multi-omics analysis, and explore new sequencing applications. It will also accelerate advancing precision medicine, clinical translation, and AI-driven insights. Together, these advancements establish JCBio as a hub for high-level genomic research and multi-omics innovation.
Established in 2023, MGI’s DCS Lab Initiative was designed to provide laboratories worldwide with comprehensive sequencing solutions. The program takes its name from three of MGI’s core technologies: DNA genomics, Cell omics, and Spatial omics. This initiative, which focuses on frontier science for international markets, represents the company’s ability to provide end-to-end products across various applications.
The initiative has already led to research globally. At MGI’s Customer Experience Centre in Australia, tools such as DNBelab-C4 for single-cell omics and STOmics Stereo-seq for spatial transcriptomics have contributed to breakthroughs in cancer research, medicine, and agriculture. Building on this record, the MGI Tech and JCBio partnership extends the initiative to South Korea, underscoring the country’s expanding role in Asia’s fast-growing biotechnology sector.
“We are excited to partner with JCBio, an organization that shares our commitment to scientific excellence and innovation,” said Dr. Roy Tan, Director of MGI Northeast Asia. “With the DCS Lab Project, we are not only deploying sequencing platforms but establishing a hub for multi-omics discovery that equips South Korea’s research community with the tools to drive frontier science and improve human health.”
JCBio’s leadership emphasized the impact of the collaboration: “This partnership with MGI is a game-changer for South Korea’s research community,” added JaeChan Yoo, CEO of JCBio. “By integrating long- and short-read sequencing technologies, the DCS Lab enables researchers to tackle complex biological questions and accelerate breakthroughs in precision medicine and multi-omics research. Together, we are supporting South Korea’s growing role in global genomics research.”
